BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 22 Publications

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Genes Dev, 2017, 31(6):553-566

PubMed: 28404630 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	M365U2tqdmG\|ZTDhd5NigQ>?			MYfpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS\|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR\|UxKD1iMUPuUUk>	M{jWdFE6Pzd6MEK0
IGF-Sal	NXnzfYt1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=			MWrJR\|UxRTdibl2=	NGDoUZUyQTd5OECyOC=>
CCRF-CEM (ALL)	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIPQNJh,PSEQvF2=	NHrrU4RFVVOR	M4TVdGlEPTB;MT6yN\|kh\|ryP	Mn\GNVk6QTZ{N{K=
PC3	M1\Y[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4DVUp42KM7:TR?=	NELQU21FVVOR	MmDGTWM2OD1yLkm2OUDPxE1?	NF3lWGkyQTl7NkK3Ni=>
JD	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVP+OUDPxE1?	NFrqc29FVVOR	MlPGTWM2OD1yLkO5NUDPxE1?	MmCzNVk6QTZ{N{K=
DU145	NGi4dHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NESzbWl,PSEQvF2=	NHTHNYFFVVOR	MXfJR\|UxRTFwNE[1JO69VQ>?	MkKyNVk6QTZ{N{K=
KAG	M3q1dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnvXglUh\|ryP	M2nadGROW09?	NYT3NZFtUUN3ME2xMlY3PSEQvF2=	MnjTNVk6QTZ{N{K=
K-562 (CML)	MnfDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWT1WYtOhjVizszN	MUXEUXNQ	MknETWM2OD1{LkOwNkDPxE1?	NXzR[XI5OTl7OU[yO\|I>
B6-P210 (Murine ALL)	NY\qTJZ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFfBeGd,PSEQvF2=	M1vTdmROW09?	NX3y[GZDUUN3ME2xMlI6OyEQvF2=	NF7u[2cyQTl7NkK3Ni=>
LN CAP-FGC	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYX+OUDPxE1?	M4PlSWROW09?	M3L3TGlEPTB;MT60N\|Qh\|ryP	NILLUW8yQTl7NkK3Ni=>
VW	Mn3hS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnznglUh\|ryP	NETicoxFVVOR	M{OxOWlEPTB;MD6wNVkh\|ryP	MnLQNVk6QTZ{N{K=
MV411 (B Myelomonocytic)	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3Lwbp42KM7:TR?=	MVPEUXNQ	NF;MTppKSzVyPUCuN\|Mh\|ryP	NX65cFYyOTl7OU[yO\|I>
MDA-PCa-2b	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkTlglUh\|ryP	NFjNNIpFVVOR	MX3JR\|UxRTBwMEm4JO69VQ>?	NX\SV4VZOTl7OU[yO\|I>
LG	MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2H5dp42KM7:TR?=	M2PnbGROW09?	MWLJR\|UxRTBwMEO4JO69VQ>?	NI\iWGkyQTl7NkK3Ni=>
RS411 (B cell precursor-ALL)	NF:zXGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NI\xS3J,PSEQvF2=	MUTEUXNQ	NVLBS21iUUN3ME2wMlExOiEQvF2=	NXXVWIhPOTl7OU[yO\|I>
22-r-1	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4PSfp42KM7:TR?=	MYnEUXNQ	NXLF[GJHUUN3ME2wMlE4PSEQvF2=	NFX6PGYyQTl7NkK3Ni=>
5838	MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlnJglUh\|ryP	NV3oUmh4TE2VTx?=	NVjzT45qUUN3ME2wMlA{PCEQvF2=	MVOxPVk6PjJ5Mh?=
P388 (Murine)	NHHMWHlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX7+OUDPxE1?	NHfw[\|VFVVOR	NFTo[npKSzVyPUSuNlch\|ryP	MojYNVk6QTZ{N{K=
A2780/S	M{HxVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXPoUmp1hjVizszN	NIHxXJRFVVOR	NVzoWXJUUUN3ME2wMlEzOiEQvF2=	MWixPVk6PjJ5Mh?=
RDES	NUfGXZp7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEi0OJJ,PSEQvF2=	NXzBU20zTE2VTx?=	M{P2WWlEPTB;MD6wNVIh\|ryP	M{XzNFE6QTl4Mkey
B6-T315I (Murine B-ALL)	NFT4NIJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXjyRplXhjVizszN	NF[1PZRFVVOR	MnrJTWM2OD1{LkizJO69VQ>?	M2mybVE6QTl4Mkey
TOV 112D	NWLVcoJyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4XnT542KM7:TR?=	MmX5SG1UVw>?	M3Gy[WlEPTB;Mj6xOFYh\|ryP	MUCxPVk6PjJ5Mh?=
TC32	M{f0R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlLpglUh\|ryP	MlvzSG1UVw>?	MVrJR\|UxRTBwMEC4JO69VQ>?	MVOxPVk6PjJ5Mh?=
HL60 (acute myelocytic)	NWrTPGpMT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEHKO5d,PSEQvF2=	M3\OWmROW09?	M3fWWWlEPTB;MD6xNkDPxE1?	NIXFcYcyQTl7NkK3Ni=>
TOV 21G	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXT+OUDPxE1?	MVXEUXNQ	MYHJR\|UxRTRwMke5JO69VQ>?	NUfsbGU4OTl7OU[yO\|I>
TC71	M2faXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M37OeZ42KM7:TR?=	MlvkSG1UVw>?	MUHJR\|UxRTBwMEG0JO69VQ>?	MlTBNVk6QTZ{N{K=
HPN-ALL (T-cell)	NFSxW5NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NELsem5,PSEQvF2=	M2nkcWROW09?	MmO4TWM2OD1yLkWyJO69VQ>?	NX\hXJJDOTl7OU[yO\|I>
A2780R	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFPMU5N,PSEQvF2=	M1rO[mROW09?	MlHPTWM2OD1zLkW2OEDPxE1?	NIXl[oYyQTl7NkK3Ni=>
Rh1	NU\ibWgyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NX7WUndThjVizszN	NFzmUpFFVVOR	M13FSGlEPTB;MD6wNlch\|ryP	NHLjWoYyQTl7NkK3Ni=>
Kasumi-1 (acute myeloid)	NG\6SmNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHfu[YV,PSEQvF2=	MXTEUXNQ	NGjCTodKSzVyPUCuNVYh\|ryP	NEDlN4cyQTl7NkK3Ni=>
sk-ov-3	M{TWSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVLR[WRkhjVizszN	NXHublFnTE2VTx?=	M4XufmlEPTB;NT6xJO69VQ>?	MmHwNVk6QTZ{N{K=
ME	M1[ye2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnnQglUh\|ryP	MYnEUXNQ	NHXM[4dKSzVyPUCuNFE2KM7:TR?=	MnrSNVk6QTZ{N{K=
L1210 (Murine lymphocytic)	NHXGUJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml7EglUh\|ryP	Mm\XSG1UVw>?	Mn3zTWM2OD1{LkO5JO69VQ>?	MojMNVk6QTZ{N{K=
sw-626	NVnzblVYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mo\pglUh\|ryP	NGXTcGxFVVOR	NEnEcFdKSzVyPUKuN\|A3KM7:TR?=	NVnLc2l1OTl7OU[yO\|I>
CTR	NFj4epdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlfBglUh\|ryP	MWPEUXNQ	MkPMTWM2OD1yLkK1N{DPxE1?	NUnKepQ1OTl7OU[yO\|I>
ML2 (Myelomonocytic)	MlzLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXn6enJIhjVizszN	NIHNd41FVVOR	MmHwTWM2OD1yLkC5JO69VQ>?	MXexPVk6PjJ5Mh?=
ovcar-3	M{S0W2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVrFbpNThjVizszN	MkDPSG1UVw>?	MXTJR\|UxRTVizszN	MU[xPVk6PjJ5Mh?=
Rh36	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NID6XZN,PSEQvF2=	NFvafnNFVVOR	MnjrTWM2OD1zLkSzNkDPxE1?	NGT3XWkyQTl7NkK3Ni=>
MOLM-13 (acute myeloid)	NW[y[3hNT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHjHc2p,PSEQvF2=	NITZSFlFVVOR	MUPJR\|UxRTBwNEKg{txO	NXvyXlR5OTl7OU[yO\|I>
ovcar-4	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlK4glUh\|ryP	MVLEUXNQ	MlLWTWM2OD1zIN88US=>	MYixPVk6PjJ5Mh?=
Rh41	M4LEZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3LVVZ42KM7:TR?=	M4DXZ2ROW09?	NHjUcHhKSzVyPUCuNFA2KM7:TR?=	MYixPVk6PjJ5Mh?=
Mutz 2 (acute myeloid)	M{j5TGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXn2WopshjVizszN	MlzjSG1UVw>?	NWPsVndxUUN3ME2xMlE2KM7:TR?=	NVzFfmdHOTl7OU[yO\|I>
ovcar-5	MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWj+OUDPxE1?	MY\EUXNQ	M1;B[WlEPTB;MD6wOUDPxE1?	NHTXVYcyQTl7NkK3Ni=>
RD1	NX;ybGJlT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1jGOJ42KM7:TR?=	NYf0XmVxTE2VTx?=	NFiwc29KSzVyPUCuNFY5KM7:TR?=	MoXONVk6QTZ{N{K=
OCI-AML 2 (acute myeloid)	NYPEOWhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXX+OUDPxE1?	M{XrUmROW09?	NX\QOmpTUUN3ME2zMlM{KM7:TR?=	M{DVdlE6QTl4Mkey
786-O	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2SyW542KM7:TR?=	M4nQ[GROW09?	NWDHTlNwUUN3ME2xMlY1PyEQvF2=	NHThR\|cyQTl7NkK3Ni=>
A673	NGfqV2pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEDwS5Z,PSEQvF2=	MUXEUXNQ	MoLXTWM2OD1yLkSwPEDPxE1?	MYGxPVk6PjJ5Mh?=
TALL-1 (T-cell)	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnfHglUh\|ryP	MXnEUXNQ	M{TTSmlEPTB;MT6yPEDPxE1?	NGHFS5EyQTl7NkK3Ni=>
151-B	M4X5RWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFr0NJp,PSEQvF2=	MXXEUXNQ	MlvlTWM2OD1{Lk[3JO69VQ>?	MVqxPVk6PjJ5Mh?=
PFSK-1	MkfiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlLqglUh\|ryP	NHSwXHBFVVOR	M1znVmlEPTB;MD6xN\|Ih\|ryP	MmjvNVk6QTZ{N{K=
THP-1	NIC2[VVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEL0boF,PSEQvF2=	NV;lVG9KTE2VTx?=	MnfqTWM2OD14LkW4JO69VQ>?	NVTve5JsOTl7OU[yO\|I>
HEK293	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXrVTWNthjVizszN	MVXEUXNQ	Mlj0TWM2OD1yLkmxOUDPxE1?	MoPkNVk6QTZ{N{K=
DAOY	M{jqVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUD+OUDPxE1?	M1Xi[mROW09?	MoG3TWM2OD1zLkm3PUDPxE1?	NH\wN2cyQTl7NkK3Ni=>
SET2	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NW\1eG9lhjVizszN	M4TX[WROW09?	NWfHWHRZUUN3ME2wMlI6QCEQvF2=	MYOxPVk6PjJ5Mh?=
HTB-46	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{PYXJ42KM7:TR?=	NEXUV2pFVVOR	M2H0RWlEPTB;NT6yOUDPxE1?	MWKxPVk6PjJ5Mh?=
SK-NAS	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXH+OUDPxE1?	MofFSG1UVw>?	MV;JR\|UxRTBwNEm3JO69VQ>?	NFfjO5cyQTl7NkK3Ni=>
CTLL2	M4L1UGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVPqN4JLhjVizszN	NH7OXpFFVVOR	NWq1d3JRUUN3ME6xMlAxKM7:TR?=	M1HneFE6QTl4Mkey
HTB-47	NFPuPGxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4G5Vp42KM7:TR?=	NX3kU5g5TE2VTx?=	NFrJNJZKSzVyPUKuNFU3KM7:TR?=	NWLsOlNqOTl7OU[yO\|I>
LAN-1	MkTLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYj+OUDPxE1?	NYXQOFNUTE2VTx?=	NYjkNmltUUN3ME2wMlA1KM7:TR?=	MmDXNVk6QTZ{N{K=
ST486	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mmm1glUh\|ryP	NV61[2tvTE2VTx?=	NVniNVdEUUN3ME2xMlE6KM7:TR?=	M121XFE6QTl4Mkey
HS766T	MkPiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3vjb542KM7:TR?=	NETZRmVFVVOR	M13LXGlEPTB;Mj6wNFEh\|ryP	MYmxPVk6PjJ5Mh?=
IMR-32	NV3CbGo2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXjXUoJWhjVizszN	MXfEUXNQ	M33VNGlEPTB;MD6yOlEh\|ryP	MXexPVk6PjJ5Mh?=
Daudi (Burkitt's)	NEf2bVhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYXWVm93hjVizszN	MmrySG1UVw>?	NYm0b4JLUUN3ME2yMlY{PyEQvF2=	MmDVNVk6QTZ{N{K=
Aspc-1	MkXkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NULJ[HZYhjVizszN	NGCwT\|ZFVVOR	NGnuV2dKSzVyPUCuN\|c6KM7:TR?=	NEjSV48yQTl7NkK3Ni=>
SK-NSH	M13FNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{DLV542KM7:TR?=	MX7EUXNQ	Mm\wTWM2OD1yLkGzPUDPxE1?	NU\iU3FYOTl7OU[yO\|I>
MEC-1 (Chronic B cell)	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEXzOXR,PSEQvF2=	NEP3RpFFVVOR	M1zheGlEPTB;Mj62N\|ch\|ryP	MmTvNVk6QTZ{N{K=
Capan-2	Mlr1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIrRV3p,PSEQvF2=	MnfDSG1UVw>?	MXnJR\|UxRTFwN{e0JO69VQ>?	NXrufIJsOTl7OU[yO\|I>
SHSY5Y	NGK0Ro5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmThglUh\|ryP	MkO4SG1UVw>?	MlP2TWM2OD1yLkGwOkDPxE1?	MofENVk6QTZ{N{K=
U937 (Histioocytic)	M{H3ZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MniwglUh\|ryP	MnS1SG1UVw>?	MYDJR\|UxRjVwMECg{txO	MlLUNVk6QTZ{N{K=
Bxpc-1	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXz+OUDPxE1?	NEHlV4VFVVOR	MmDSTWM2OD1zLkmyOEDPxE1?	M3vnflE6QTl4Mkey
Bxpc-3	M{SwTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmrlglUh\|ryP	NXT5T2s5TE2VTx?=	Mk\6TWM2OD53LkCwJO69VQ>?	M1\ZXVE6QTl4Mkey
HTB-92	NELsVJNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnvVglUh\|ryP	NIjO[\|hFVVOR	M4fqemlEPTB;MT6wNkDPxE1?	NIXIeoMyQTl7NkK3Ni=>
OCI-LY10 (B-cell)	NUTLelJiT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWj0Uo9FhjVizszN	M3voZWROW09?	NGm3UGhKSzVyPUCuOFUh\|ryP	MmrsNVk6QTZ{N{K=
PANC-1	MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVf+OUDPxE1?	NU\SSFVLTE2VTx?=	NUjqTFBPUUN3ME61MlAxKM7:TR?=	NF\aeocyQTl7NkK3Ni=>
To184.T	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnXIglUh\|ryP	MoLySG1UVw>?	MnHDTWM2OD1yLkS2PUDPxE1?	M3fRXlE6QTl4Mkey
OCI-LY19 (B-cell)	M3eyTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2\aTZ42KM7:TR?=	NX;HS5lsTE2VTx?=	NHfsTnFKSzVyPUCuOEDPxE1?	M{H1NlE6QTl4Mkey
PANC-1 BM	MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXTSfopFhjVizszN	NVzHbG96TE2VTx?=	NXfXNos3UUN3ME61MlAxKM7:TR?=	NFS4T5QyQTl7NkK3Ni=>
SA-4	Ml;FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUfSTol[hjVizszN	MlWySG1UVw>?	NH;yTJBKSzVyPUGuN\|AyKM7:TR?=	M1jrRlE6QTl4Mkey
RPMI 8226	NGPOWIRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWn+OUDPxE1?	MmD1SG1UVw>?	NUDSSoVzUUN3ME2xMlI6OyEQvF2=	NYPQWJg2OTl7OU[yO\|I>
HPAF-II	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYL+OUDPxE1?	M4HJdGROW09?	MXvJR\|UxRTBwNkS0JO69VQ>?	MXSxPVk6PjJ5Mh?=
SHP-77	MlLCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUH+OUDPxE1?	MlTjSG1UVw>?	NWLlZnVFUUN3ME2xMlg5QCEQvF2=	NXvxOodJOTl7OU[yO\|I>
U266 B1	NH\jZWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnTwglUh\|ryP	NXrHfYR7TE2VTx?=	NE\GZnBKSzVyPUGuOlY6KM7:TR?=	MV2xPVk6PjJ5Mh?=
Hs700t	MnjQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXj+OUDPxE1?	M3L3UGROW09?	NVHJfJZEUUN3ME2wMlI{OSEQvF2=	MWexPVk6PjJ5Mh?=
NCI-446	M{fUTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUL+OUDPxE1?	NXf6SpU5TE2VTx?=	Mlu2TWM2OD1zLkG1OEDPxE1?	NFn3R4IyQTl7NkK3Ni=>
H929	M2TsO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlPlglUh\|ryP	NYLv[o1pTE2VTx?=	NWP4RYFJUUN3ME2wMlAyPCEQvF2=	MmHDNVk6QTZ{N{K=
PL45	NFjXN3FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEnn[nR,PSEQvF2=	MlLrSG1UVw>?	NH;oe5lKSzVyPUKuNlU2KM7:TR?=	NIrt[2QyQTl7NkK3Ni=>
NCI-H383	NU\5bFkxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M37tPJ42KM7:TR?=	NGH6OIlFVVOR	NYOz[np1UUN3ME61MlAxKM7:TR?=	NIe4b4syQTl7NkK3Ni=>
JJN3	M3L1OWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3r2cJ42KM7:TR?=	MUPEUXNQ	MY\JR\|UxRTJwNEOzJO69VQ>?	NHLrTIoyQTl7NkK3Ni=>
SU.86.86	NXywboxXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFXaPGd,PSEQvF2=	MUTEUXNQ	NUX4TFVGUUN3ME2yMlY4OiEQvF2=	MnTGNVk6QTZ{N{K=
H1299	NYnwdGlpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mkf3glUh\|ryP	MkC5SG1UVw>?	NWXIVHdyUUN3ME61MlAxKM7:TR?=	NHT2ZoEyQTl7NkK3Ni=>
MDA-MB-468	NH3pSXhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnLGglUh\|ryP	NHGxepBFVVOR	MluyTWM2OD1yLkWwOEDPxE1?	NYPMVYw5OTl7OU[yO\|I>
SW1990	NH63[WdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUfkWopNhjVizszN	M13nUGROW09?	M1XiTGlEPTB;MD64NlYh\|ryP	NEDTfGoyQTl7NkK3Ni=>
Calu-6	M3L0WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoPJglUh\|ryP	MonTSG1UVw>?	MkPsTWM2OD53LkCwJO69VQ>?	NHjKN28yQTl7NkK3Ni=>
MDA-MB-231	M{\UR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXP+OUDPxE1?	NUPSRZQ1TE2VTx?=	MUfJR\|UxRTFwNkS4JO69VQ>?	MYexPVk6PjJ5Mh?=
SW-684	MoHIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX3+OUDPxE1?	NVvhOnZ4TE2VTx?=	MWnJR\|UxRjVwMECg{txO	NGDYUWIyQTl7NkK3Ni=>
H209	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmHhglUh\|ryP	M1vmdWROW09?	MUXJR\|UxRTFwMUmzJO69VQ>?	NVHyU5p7OTl7OU[yO\|I>
MDA-MB-231T	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mn3VglUh\|ryP	NGW3U3ZFVVOR	Ml:yTWM2OD53LkCwJO69VQ>?	M{D5dVE6QTl4Mkey
HT1080/S	M364dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYn+OUDPxE1?	MWfEUXNQ	MUXJR\|UxRTBwNUOxJO69VQ>?	MX:xPVk6PjJ5Mh?=
H526 0.044	M1HpOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4LQSJ42KM7:TR?=	MWXEUXNQ	NG\2OVhKSzVyPUCuNFQ1KM7:TR?=	MVOxPVk6PjJ5Mh?=
DU4475 2.431	NXqxWVExT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1rNNp42KM7:TR?=	NVPYcGtxTE2VTx?=	M3viOmlEPTB;Mj60N\|Eh\|ryP	M364RlE6QTl4Mkey
HCT116	MlvjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3HoPJ42KM7:TR?=	MoK0SG1UVw>?	NXr6WVllUUN3ME2wMlg2OiEQvF2=	MYKxPVk6PjJ5Mh?=
M109	NG\WdmxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnXKglUh\|ryP	NInHRWFFVVOR	Mln1TWM2OD1zLkC1OUDPxE1?	NUfiXHlqOTl7OU[yO\|I>
BT549	M3z2Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2PFTp42KM7:TR?=	MkD3SG1UVw>?	MYXJR\|UxRTFwNkS1JO69VQ>?	MU[xPVk6PjJ5Mh?=
HCT116/VM46	NFnSbFNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWnaVW1MhjVizszN	MnfnSG1UVw>?	M{LpWWlEPTB;MT63NFIh\|ryP	MUixPVk6PjJ5Mh?=
H460	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2\Sdp42KM7:TR?=	MYLEUXNQ	MlnSTWM2OD1yLke5OUDPxE1?	NHPIdnkyQTl7NkK3Ni=>
MCF-7	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYDrTHZEhjVizszN	MUnEUXNQ	M3TYUmlEPTB;MD6wNVYh\|ryP	MVmxPVk6PjJ5Mh?=
GEO	MlXuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmPyglUh\|ryP	NWWySZJPTE2VTx?=	NInpb2dKSzVyPUCuN\|U3KM7:TR?=	MkewNVk6QTZ{N{K=
H441 0.646	NUjrbnhIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYD+OUDPxE1?	NGP0OmJFVVOR	MUHJR\|UxRTBwNkS2JO69VQ>?	M4XFSVE6QTl4Mkey
MCF-7-807R	NYTOcY83T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2\pZp42KM7:TR?=	M3zLUWROW09?	MkHJTWM2OD1yLkS5JO69VQ>?	MWqxPVk6PjJ5Mh?=
Colo205	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYn+OUDPxE1?	MVvEUXNQ	M2\pU2lEPTB;MD6xNFQh\|ryP	NGrXOXMyQTl7NkK3Ni=>
H292	NUDD[YZoT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NID4R\|N,PSEQvF2=	NFf3UFVFVVOR	NGWycmpKSzVyPUCuO\|g5KM7:TR?=	NVzhSmh3OTl7OU[yO\|I>
BT474 (S)	NH\JT4tIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{H5b542KM7:TR?=	MXnEUXNQ	M2nwcmlEPTB;Mj60NFMh\|ryP	MVuxPVk6PjJ5Mh?=
HT-29	NEHqVlBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2jYN542KM7:TR?=	NVrrRVNyTE2VTx?=	NHjQeY5KSzVyPUKuNVA{KM7:TR?=	Mn\ENVk6QTZ{N{K=
A549	NGnU[I5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NILyb5J,PSEQvF2=	Mlj6SG1UVw>?	M{X3NmlEPTB;MD62O\|Uh\|ryP	M{fHOlE6QTl4Mkey
BT474-M1	MofMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3ryN542KM7:TR?=	MVzEUXNQ	M2Poc2lEPTB;Mj6zOlUh\|ryP	MnHmNVk6QTZ{N{K=
SW480	Ml\6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4[0U542KM7:TR?=	MUnEUXNQ	MljLTWM2OD53LkCwJO69VQ>?	MWSxPVk6PjJ5Mh?=
L2987	M2W5bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXr+OUDPxE1?	MXXEUXNQ	MnHCTWM2OD1yLkS0NkDPxE1?	MnvWNVk6QTZ{N{K=
AU565	NUDNOmhJT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2XSfJ42KM7:TR?=	MXvEUXNQ	NUTiNHh[UUN3ME20Mlk4KM7:TR?=	NWDLfGxTOTl7OU[yO\|I>
SW403	NFzZOHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWHtUmF{hjVizszN	NIfkU5dFVVOR	MVjJR\|UxRTBwMkKg{txO	MkLZNVk6QTZ{N{K=
H1437	M2jFT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mn;4glUh\|ryP	NHq5fINFVVOR	MlvpTWM2OD1yLkWyN{DPxE1?	Ml;INVk6QTZ{N{K=
BT-20	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVj+OUDPxE1?	NXf6bYVZTE2VTx?=	M{XZbGlEPTB;Mz61OlIh\|ryP	NVTQN2FVOTl7OU[yO\|I>
Colo320HSR	MlvLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFTYb49,PSEQvF2=	M1HXcWROW09?	NETiOoFKSzVyPUCuNFEyKM7:TR?=	MV:xPVk6PjJ5Mh?=
H2087	NUHJZXJ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX3+OUDPxE1?	MYnEUXNQ	NX;reGtlUUN3ME6xMlAxKM7:TR?=	MYqxPVk6PjJ5Mh?=
HCC1419	M2D3Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXL+OUDPxE1?	NYfMeZhiTE2VTx?=	NYO5OFZWUUN3ME2yMlUyPyEQvF2=	MmLuNVk6QTZ{N{K=
WiDr	NF:5OlZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlvIglUh\|ryP	MoTGSG1UVw>?	MYrJR\|UxRTBwMEe2JO69VQ>?	M2LyOFE6QTl4Mkey
H661 0.573	NV;LSZJlT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnXsglUh\|ryP	MmrsSG1UVw>?	NUTGeo5vUUN3ME2wMlU4OyEQvF2=	M1XnbVE6QTl4Mkey
HCC-38	NVTNZ5RrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHq2O3B,PSEQvF2=	NVGxZnhzTE2VTx?=	NGnYO49KSzVyPkWuNFAh\|ryP	MkjQNVk6QTZ{N{K=
LS174T	MoXIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUCyUpFWhjVizszN	MYPEUXNQ	NYW5PVdDUUN3ME2wMlU{PSEQvF2=	NFziO2syQTl7NkK3Ni=>
H211	M1T4Xmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{PkUp42KM7:TR?=	NGL0WYRFVVOR	NHrs[I1KSzVyPUCuO\|M{KM7:TR?=	MVWxPVk6PjJ5Mh?=
HCC70	NHq3T4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2n2cZ42KM7:TR?=	NXfrc3ViTE2VTx?=	MWHJR\|UxRTFwNUWg{txO	MUOxPVk6PjJ5Mh?=
SW116	M2L5WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkTOglUh\|ryP	NGD1UXJFVVOR	MXjJR\|UxRTBwME[3JO69VQ>?	MX:xPVk6PjJ5Mh?=
H513	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUTzZmhWhjVizszN	NUTqTHB5TE2VTx?=	NUHs[5VRUUN3ME20MlQ1QCEQvF2=	NIjmOGEyQTl7NkK3Ni=>
MDA-MB-157	NFG0eVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVX+OUDPxE1?	MXnEUXNQ	NX\qdmI6UUN3ME2wMlA{PiEQvF2=	NXPjZWtnOTl7OU[yO\|I>
H2052	MkHmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnvxglUh\|ryP	M2TTVWROW09?	M{i3NmlEPTB;MT6wOUDPxE1?	NWnMOYZTOTl7OU[yO\|I>
MDA-MB-415	NF3HNlNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1LrUZ42KM7:TR?=	NHn5WFdFVVOR	NF;NVWlKSzVyPkWuNFAh\|ryP	MnPTNVk6QTZ{N{K=
DLD-1	NYDx[lV3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYnTb\|FKhjVizszN	MYPEUXNQ	MXfJR\|UxRTBwOUC5JO69VQ>?	M3exTFE6QTl4Mkey
H2595	NFjD[5VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWL+OUDPxE1?	MUfEUXNQ	NUHONm5YUUN3ME20MlQ4PSEQvF2=	MnT1NVk6QTZ{N{K=
MDA-MB-435S	NXXofG06T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFf1Rpl,PSEQvF2=	NU[xWlR5TE2VTx?=	NWLScnc5UUN3ME2xMlg3QSEQvF2=	NEnE[5UyQTl7NkK3Ni=>
HCT15	NVrwSIdlT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1PW[542KM7:TR?=	MoXrSG1UVw>?	MYPJR\|UxRjFwMECg{txO	NFnEWG0yQTl7NkK3Ni=>
SK-Hep1	NGi5T5ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFn4XmV,PSEQvF2=	M{fpZ2ROW09?	MV3JR\|UxRTBwMUS2JO69VQ>?	NX7FOW1JOTl7OU[yO\|I>
MDA-MB-436	M3PFRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWT2d5hvhjVizszN	NHXHSIFFVVOR	MWjJR\|UxRTVwNUCyJO69VQ>?	MYCxPVk6PjJ5Mh?=
KM12C	NGTC[IZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmG4glUh\|ryP	NF3LbHNFVVOR	MWDJR\|UxRTBwMEW0JO69VQ>?	NH35UZcyQTl7NkK3Ni=>
HEPG2	NHu5eY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnTYglUh\|ryP	NH7pWlNFVVOR	MUfJR\|UxRTBwMEK1JO69VQ>?	MXexPVk6PjJ5Mh?=
MDA-MB-453	M{npfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoTjglUh\|ryP	MYPEUXNQ	M2DIcWlEPTB;MT64Olkh\|ryP	M{j1NFE6QTl4Mkey
KM12SM	NIm5Xm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUH+OUDPxE1?	NGrD[m5FVVOR	M2TmOGlEPTB;MD6wOVkh\|ryP	MkPqNVk6QTZ{N{K=
1483	NFH3VINIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVL+OUDPxE1?	NYTtSYtmTE2VTx?=	M1rxXGlEPTB;Mj6xPUDPxE1?	NHLsTHQyQTl7NkK3Ni=>
Hs578t	M3zvXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2nqZZ42KM7:TR?=	NGXqdW5FVVOR	MYHJR\|UxRTFwMki3JO69VQ>?	M1nqWVE6QTl4Mkey
LS180	NFfDXVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkPHglUh\|ryP	NX\Vd2c2TE2VTx?=	M3XsbGlEPTB;MD62PVYh\|ryP	NEPvUXEyQTl7NkK3Ni=>
FaDu	M2rOTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH3mUoF,PSEQvF2=	MWLEUXNQ	M3;UT2lEPTB;MT6yO{DPxE1?	NGTafZUyQTl7NkK3Ni=>
ZR-75-1	NV7xcYI4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlW5glUh\|ryP	MnmySG1UVw>?	NVi4UXhVUUN3ME2yMlA5PCEQvF2=	Ml\WNVk6QTZ{N{K=
LS513	M3;Bemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4G4Xp42KM7:TR?=	NIrVSYpFVVOR	NIDMT5ZKSzVyPUCuNVM2KM7:TR?=	NWfO[VB1OTl7OU[yO\|I>
Detroit.562	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX[5SYRXhjVizszN	NIm2NHdFVVOR	NGrufG5KSzVyPUGuNVQh\|ryP	MX:xPVk6PjJ5Mh?=
ZR-75-30	M3LFV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlHsglUh\|ryP	NU\5XpBCTE2VTx?=	NYfZPWNsUUN3ME61MlAxKM7:TR?=	NEPHXogyQTl7NkK3Ni=>
RKO-PM	M3K1Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXS2fYRLhjVizszN	MkOxSG1UVw>?	MmT2TWM2OD1yLkKzNkDPxE1?	M4PzO\|E6QTl4Mkey
Cal.27	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mlu3glUh\|ryP	MoO4SG1UVw>?	NVPKfWFVUUN3ME2yJO69VQ>?	NWXoTWJwOTl7OU[yO\|I>
KPL4	M{DFTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml3yglUh\|ryP	NInLUINFVVOR	M1nrNmlEPTB;MT6yOVIh\|ryP	NH\PcYIyQTl7NkK3Ni=>
PKO-RM13	NGCxXnZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXjsSndmhjVizszN	NYfaSGRmTE2VTx?=	MV7JR\|UxRTBwNEK1JO69VQ>?	MVuxPVk6PjJ5Mh?=
HS.53.T	M1LiXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoPvglUh\|ryP	MlG2SG1UVw>?	MnXoTWM2OD1yLke5JO69VQ>?	NIr6ZVgyQTl7NkK3Ni=>
EMT6	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M33sfJ42KM7:TR?=	MnzRSG1UVw>?	Mmn5TWM2OD1yLkiwOkDPxE1?	NGqwN2syQTl7NkK3Ni=>
SNU-C1	NX21O5pPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3[1b542KM7:TR?=	MVnEUXNQ	MmK1TWM2OD1yLkCwO{DPxE1?	MV6xPVk6PjJ5Mh?=
SQCCY1	NYP2cmZiT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYD+OUDPxE1?	NWnpSGhsTE2VTx?=	M{DTW2lEPTB;MD63PUDPxE1?	MUWxPVk6PjJ5Mh?=
SW480	NYO2TJJyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUP+OUDPxE1?	NYDORohKTE2VTx?=	MYXJR\|UxRTBwMEO3JO69VQ>?	NUTWRXM2OTl7OU[yO\|I>
SCC9	MkDDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHr1bYF,PSEQvF2=	M4HVcmROW09?	NFrRWZJKSzVyPUCuO\|Uh\|ryP	MlvkNVk6QTZ{N{K=
SK-LMS-1	MnLLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmHrglUh\|ryP	NWiw[phHTE2VTx?=	NUmyPINvUUN3ME2wMlY5PyEQvF2=	M2DRdVE6QTl4Mkey
SCC25	M33TO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3Lpcp42KM7:TR?=	NF3FRWFFVVOR	MUDJR\|UxRTBwNkig{txO	NW\5[pR5OTl7OU[yO\|I>
U87	NVexOGM2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYj+OUDPxE1?	M2[zTWROW09?	M4DWTWlEPTB;MD65OUDPxE1?	MoSwNVk6QTZ{N{K=
SCC15	M13sNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVf+OUDPxE1?	MUPEUXNQ	NGTqT4RKSzVyPUCuOlch\|ryP	M1HseFE6QTl4Mkey
T98G	NHvNc3dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmHsglUh\|ryP	M{XWemROW09?	MWHJR\|UxRTFwMkG4JO69VQ>?	NX;2R2M6OTl7OU[yO\|I>
SCC4	MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVf4dXBVhjVizszN	M3naOmROW09?	MnTQTWM2OD1yLk[zJO69VQ>?	MX[xPVk6PjJ5Mh?=
U118	M{Tldmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mn[3glUh\|ryP	NEexUpZFVVOR	M{jMXWlEPTB;MT62NVgh\|ryP	MXGxPVk6PjJ5Mh?=
TU167	MkTHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGXNbVR,PSEQvF2=	M3nDbmROW09?	NV3ZfWdRUUN3ME20MlUzKM7:TR?=	NYrxVlJrOTl7OU[yO\|I>
NCI-H727	MmjIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3LLbp4yOOLCit88US=>	M2DJWmROW09?	MVXJR\|UxRTR{ODDuUS=>	NV;3WlltOjB\|OEW3OFc>
NCI-H720	NEPYdGxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX\+NVDjiIsQvF2=	MmTISG1UVw>?	Mni5TWM2OD1{Lkig{txO	Mmf1NlA{QDV5NEe=
NCI-H835	M4PBfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYP+NVDjiIsQvF2=	MknMSG1UVw>?	Ml7CTWM2OD1zIN88US=>	Mnm0NlA{QDV5NEe=
NCI-H727	MWHLbY5ie2ViYYPzZZk>	M1HZSJ4yOOLCit88US=>	MW\EUXNQ	NFzWc3FqdmirYnn0d{Bkd26\|dHn0eZRqfmViSVfGNXIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MYeyNFM5PTd2Nx?=
RD	NY\vN4E{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnnjglEx6oDMzszN		NWDk[nh1UUN3ME2xMlEzKML3TR?=	NInKSI0zOTJ7OEe0OS=>
Rh41	NFG5[5lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{PWdp4yOOLCit88US=>		M1XDUGlEPTB;MD6wO{DDvU1?	MVOyNVI6QDd2NR?=
Rh18	MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWGyWHN1hjFy4pEK{txO		NUnCOnN5UUN3ME20Mlk3KML3TR?=	NEDLUo4zOTJ7OEe0OS=>
Rh30	NFf6fItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFjtXWF,OTEkgJtOwG0>		MXTJR\|UxRTBwMUmgxtVO	MYeyNVI6QDd2NR?=
BT-12	MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mnr4glEx6oDMzszN		Ml7tTWM2OD1yLke4JOK2VQ>?	M2XNXVIyOjl6N{S1
CHLA-266	NI\VbmFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXXpU45vhjFy4pEK{txO		MWLJR\|UxRTBwOEmgxtVO	MXyyNVI6QDd2NR?=
TC-71	MmjUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1nRSZ4yOOLCit88US=>		Mmf0TWM2OD1yLkGxJOK2VQ>?	NXLp[GdLOjF{OUi3OFU>
CHLA-9	MlHBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYP+NVDjiIsQvF2=		MVfJR\|UxRTBwMUKgxtVO	NXLqcXhkOjF{OUi3OFU>
CHLA-10	M3nQb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFXwdo5,OTEkgJtOwG0>		NUnpZndDUUN3ME2wMlYzKML3TR?=	MYCyNVI6QDd2NR?=
CHLA-258	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYXuUHhohjFy4pEK{txO		NEjhRWtKSzVyPUCuNlchyrWP	NVvDNoZVOjF{OUi3OFU>
GBM2	NXfnV5NQT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlfwglEx6oDMzszN		MWnJR\|UxRTFwNEegxtVO	MV[yNVI6QDd2NR?=
NB-1643	M1vxWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEnqdm5,OTEkgJtOwG0>		NFjmUFBKSzVyPUCuNVIhyrWP	MmfDNlEzQTh5NEW=
NB-EBc1	MlSyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlnrglEx6oDMzszN		NVLmR5JkUUN3ME2wMlM2KML3TR?=	NVzjVI5wOjF{OUi3OFU>
CHLA-90	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUC2eIlRhjFy4pEK{txO		NYLOS\|hJUUN3ME2wMlc4KML3TR?=	M1\pPFIyOjl6N{S1
CHLA-136	NH2xdJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWrDNZVHhjFy4pEK{txO		Mk\wTWM2OD1yLkWyJOK2VQ>?	M2fCflIyOjl6N{S1
NALM-6	M4PyeWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4LIPZ4yOOLCit88US=>		NVrpe2RYUUN3ME2wMlQ6KML3TR?=	NVrZPIZqOjF{OUi3OFU>
COG-LL-317	NVnXS3lnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4KzPZ4yOOLCit88US=>		MnLjTWM2OD1zLkO4JOK2VQ>?	M4TOelIyOjl6N{S1
RS4;11	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NH\XUm5,OTEkgJtOwG0>		NX\MRmdYUUN3ME2wMlM5KML3TR?=	MXSyNVI6QDd2NR?=
MOLT-4	MlnZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVPWOoQzhjFy4pEK{txO		MonUTWM2OD1yLkWzJOK2VQ>?	NHvZcWUzOTJ7OEe0OS=>
CCRF-CEM	NWfRWVQ6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHXu[G5,OTEkgJtOwG0>		MYnJR\|UxRTFwMUOgxtVO	M1XSfFIyOjl6N{S1
Kasumi-1	MoLIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX30XJFIhjFy4pEK{txO		M1HB[WlEPTB;MT6yJOK2VQ>?	NXTBboxNOjF{OUi3OFU>
Karpas-299	NUDyNFdvT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mn[0glEx6oDMzszN		NULPPWNJUUN3ME2xMlY1KML3TR?=	NHL5eYwzOTJ7OEe0OS=>
Ramos-RA1	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4jEPZ4yOOLCit88US=>		NGHG[lBKSzVyPUGuN\|EhyrWP	NITMeG8zOTJ7OEe0OS=>
Rh30	Mn\rSpVv[3Srb36gZZN{[Xl?			M2P3eolv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	M4jORlI2QTJ3M{e4
Rh41	NWnF[nB6TnWwY4Tpc44h[XO\|YYm=			MnzlbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	MorRNlU6OjV\|N{i=
RD	M17veGZ2dmO2aX;uJIF{e2G7			M{HrcYlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	NEjYc5QzPTl{NUO3PC=>
A549	NV7ZeHpkU2mwYYPlJIF{e2G7	M{fCTVAvPeLCit88US=>	NFy2XYZFVVOR	M2POb4lvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	M3K2UVI3QTJ6NUe4
NCI-H358	Mn7mT4lv[XOnIHHzd4F6	NV;YVldGOC534pEK{txO	M17YZmROW09?	NHX3OIFqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>?	NXrFT2lzOjZ7Mki1O\|g>
A549	NUjWbFhxTnWwY4Tpc44h[XO\|YYm=	M3;ZdFAvPeLCit88US=>	NHGydVFFVVOR	MULjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	M3viUVI3QTJ6NUe4
NCI-H358	NEfXUZVHfW6ldHnvckBie3OjeR?=	M361Z\|AvPeLCit88US=>	NGHKPWtFVVOR	MX7jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	NXXrVGhHOjZ7Mki1O\|g>
A549	NGLueYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2jGdp4yOOLCit88US=>	MWXEUXNQ	M{Tx[2lEPTB;MD63OkDPxE1?	NWrvSnNVOjZ7Mki1O\|g>
NCI-H358	M{HLUmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUL+NVDjiIsQvF2=	MUfEUXNQ	MVrJR\|UxRTFwMEmg{txO	NHrvfHQzPjl{OEW3PC=>
A549	MmfxRZBweHSxc3nzJIF{e2G7	NHXo[4gxNjYkgJtOwG0>	MkHXSG1UVw>?	NGXld2VqdmS3Y3XzJGFxd3C2b4Ppdy=>	NVSxW29POjZ7Mki1O\|g>
NCI-H358	M3W2TmFxd3C2b4Ppd{Bie3OjeR?=	M4faclAvPeLCit88US=>	NFviUVhFVVOR	MoLVbY5lfWOnczDBdI9xfG:\|aYO=	Mki5NlY6Ojh3N{i=
A549	MUXGeY5kfGmxbjDhd5NigQ>?	MmLxNE426oDMzszN	NX;zS417TE2VTx?=	NEPYZ5Bz\WS3Y3XzJJdwfW6mIHPsc5N2emV?	NXLaS\|hkOjZ7Mki1O\|g>
NCI-H358	M3vvWGZ2dmO2aX;uJIF{e2G7	MnPiNE426oDMzszN	NVSwbpNuTE2VTx?=	NWjnT4tZemWmdXPld{B4d3WwZDDjcI9{fXKn	MmXRNlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; PubMed: 26136493 Neuro Oncol (C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.	26136493
Growth inhibition assay	Cell viability; PubMed: 30754629 Molecules Response of SK-CO-1 to various drugs and drug combinations.	30754629

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	- Collapse Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324，Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 22 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 22 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)